Matthias B. Moor
Bern, BE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Sex differences in the long-term tolerability of BNT162b2 in children and adolescents.
Journal: Molecular and cellular pediatrics
Published: January 25, 2026
The renal response to FGF23 shifts from phosphaturia toward inflammation in kidney disease.
Journal: Journal of cell communication and signaling
Published: November 02, 2025
The Long-Term Tolerability of BNT162b2 in Children and Adolescents (the CoVacU18 Study).
Journal: Deutsches Arzteblatt international
Published: August 18, 2024
Fgf23 expression increases atherosclerotic plaque burden in male ApoE deficient mice.
Journal: Atherosclerosis
Published: July 01, 2024
Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study.
Journal: Biology of sex differences
Published: April 12, 2024
Apixaban dosing in hemodialysis - can drug level monitoring mitigate controversies?
Journal: BMC nephrology
Published: February 10, 2024
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in children under 5 years.
Journal: The Journal of clinical investigation
Published: September 05, 2023
Defining the molecular response to ischemia-reperfusion injury and remote ischemic preconditioning in human kidney transplantation.
Journal: PloS one
Published: September 01, 2023
HPV Vaccination in Immunosuppressed Patients with Established Skin Warts and Non-Melanoma Skin Cancer: A Single-Institutional Cohort Study.
Journal: Vaccines
Published: July 04, 2023
Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.
Journal: JAMA network open
Published: October 18, 2022
Last Updated: 09/26/2026